| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = -$226 ) |
| | 2024 | 2021 | PRECYTE INC | 10341 WINDSOR VIEW DR | POTOMAC | MD | 20854-4000 | MONTGOMERY | USA | R44CA203455 | Optimization and Validation of an indicator cell assay for blood-based diagnosis of lung cancer | 000 | 4 | NIH | 1/10/2024 | -$226 |
| | 2024 | 2020 | PRECYTE INC | 10341 WINDSOR VIEW DR | POTOMAC | MD | 20854-4000 | MONTGOMERY | USA | R44AG051282 | Optimization and Validation of an Indicator Cell Assay for Blood-Based Diagnosis of Alzheimer's Disease | 000 | 5 | NIH | 6/5/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $0 ) |
| | 2023 | 2021 | PRECYTE INC | 401 TERRY AVE N | SEATTLE | WA | 98109-5263 | KING | USA | R44CA203455 | Optimization and Validation of an indicator cell assay for blood-based diagnosis of lung cancer | 000 | 4 | NIH | 5/1/2023 | $0 |
| | 2023 | 2020 | PRECYTE INC | 401 TERRY AVE N | SEATTLE | WA | 98109-5263 | KING | USA | R44AG051282 | Optimization and Validation of an Indicator Cell Assay for Blood-Based Diagnosis of Alzheimer's Disease | 000 | 5 | NIH | 6/15/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = -$20 ) |
| | 2022 | 2020 | PRECYTE INC | 454 N 34TH ST | SEATTLE | WA | 98103-8602 | KING | USA | R44AG051282 | Optimization and Validation of an Indicator Cell Assay for Blood-Based Diagnosis of Alzheimer's Disease | 000 | 5 | NIH | 6/30/2022 | $0 |
| | 2022 | 2017 | PRECYTE INC | 454 N 34TH ST | SEATTLE | WA | 98103-8602 | KING | USA | R43AG056215 | Rational drug selection for Alzheimer's disease using Indicator Cell Assay Platform (iCAP) | 000 | 1 | NIH | 6/29/2022 | -$20 |
|
| Issue Date FY: 2021 ( Subtotal = $488,587 ) |
| | 2021 | 2021 | PRECYTE INC | 454 N 34TH ST | SEATTLE | WA | 98103-8602 | KING | USA | R44CA203455 | Optimization and Validation of an indicator cell assay for blood-based diagnosis of lung cancer | 000 | 4 | NIH | 1/27/2021 | $488,587 |
|
| Issue Date FY: 2020 ( Subtotal = $996,673 ) |
| | 2020 | 2020 | PRECYTE INC | 401 TERRY N | SEATTLE | WA | 98109-5263 | KING | USA | R44AG051282 | Optimization and Validation of an Indicator Cell Assay for Blood-Based Diagnosis of Alzheimer's Disease | 000 | 5 | NIH | 5/25/2020 | $998,853 |
| | 2020 | 2019 | PRECYTE INC | 401 TERRY N | SEATTLE | WA | 98109-5263 | KING | USA | R44CA203455 | Optimization and Validation of an indicator cell assay for blood-based diagnosis of lung cancer | 000 | 3 | NIH | 9/3/2020 | $0 |
| | 2020 | 2017 | PRECYTE INC | 401 TERRY N | SEATTLE | WA | 98109-5263 | KING | USA | R43AG056215 | Rational drug selection for Alzheimer's disease using Indicator Cell Assay Platform (iCAP) | 000 | 1 | NIH | 2/8/2020 | -$2,180 |
|
| Issue Date FY: 2019 ( Subtotal = $1,508,053 ) |
| | 2019 | 2019 | PRECYTE INC | 401 TERRY N | SEATTLE | WA | 98109-5263 | KING | USA | R44CA203455 | Optimization and Validation of an indicator cell assay for blood-based diagnosis of lung cancer | 000 | 3 | NIH | 7/29/2019 | $509,200 |
| | 2019 | 2019 | PRECYTE INC | 401 TERRY N | SEATTLE | WA | 98109-5263 | KING | USA | R44AG051282 | Optimization and Validation of an Indicator Cell Assay for Blood-Based Diagnosis of Alzheimer's Disease | 000 | 4 | NIH | 5/6/2019 | $998,853 |
|
| Issue Date FY: 2018 ( Subtotal = $1,990,367 ) |
| | 2018 | 2018 | PRECYTE INC | 401 TERRY N | SEATTLE | WA | 98109-5263 | KING | USA | R44AG051282 | Optimization and Validation of an Indicator Cell Assay for Blood-Based Diagnosis of Alzheimer's Disease | 003 | 3 | NIH | 9/25/2018 | $19,977 |
| | 2018 | 2018 | PRECYTE INC | 401 TERRY N | SEATTLE | WA | 98109-5263 | KING | USA | R44CA203455 | Optimization and Validation of an indicator cell assay for blood-based diagnosis of lung cancer | 001 | 2 | NIH | 9/10/2018 | $70,000 |
| | 2018 | 2018 | PRECYTE INC | 401 TERRY N | SEATTLE | WA | 98109-5263 | KING | USA | R44AG051282 | Optimization and Validation of an Indicator Cell Assay for Blood-Based Diagnosis of Alzheimer's Disease | 001 | 3 | NIH | 4/27/2018 | $996,801 |
| | 2018 | 2018 | PRECYTE INC | 401 TERRY N | SEATTLE | WA | 98109-5263 | KING | USA | R44CA203455 | Optimization and Validation of an indicator cell assay for blood-based diagnosis of lung cancer | 000 | 2 | NIH | 8/13/2018 | $926,232 |
| | 2018 | 2016 | PRECYTE INC | 401 TERRY N | SEATTLE | WA | 98109-5263 | KING | USA | R44AG051282 | Optimization and Validation of an Indicator Cell Assay for Blood-Based Diagnosis of Alzheimer's Disease | 002 | 2 | NIH | 9/25/2018 | -$19,977 |
| | 2018 | 2016 | PRECYTE INC | 401 TERRY N | SEATTLE | WA | 98109-5263 | KING | USA | R43CA203455 | Development of an Indicator Cell Assay for blood-based diagnosis of lung cancer | 000 | 1 | NIH | 5/16/2018 | -$2,666 |
| | 2018 | 2016 | PRECYTE INC | 401 TERRY N | SEATTLE | WA | 98109-5263 | KING | USA | R44AG051282 | Optimization and Validation of an Indicator Cell Assay for Blood-Based Diagnosis of Alzheimer's Disease | 000 | 2 | NIH | 4/25/2018 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $299,437 ) |
| | 2017 | 2017 | PRECYTE INC | 401 TERRY N | SEATTLE | WA | 98109-5263 | KING | USA | R43AG056215 | Rational drug selection for Alzheimer's disease using Indicator Cell Assay Platform (iCAP) | 000 | 1 | NIH | 9/8/2017 | $299,437 |
|
| Issue Date FY: 2016 ( Subtotal = $1,140,354 ) |
| | 2016 | 2016 | PRECYTE INC | 970 PALO ALTO AVE | PALO ALTO | CA | 94301 | SANTA CLARA | USA | R43CA203455 | Development of an Indicator Cell Assay for blood-based diagnosis of lung cancer | 000 | 1 | NIH | 12/10/2015 | $299,947 |
| | 2016 | 2016 | PRECYTE INC | 970 PALO ALTO AVE | PALO ALTO | CA | 94301 | SANTA CLARA | USA | R44AG051282 | Optimization and Validation of an Indicator Cell Assay for Blood-Based Diagnosis of Alzheimer's Disease | 000 | 2 | NIH | 5/16/2016 | $840,407 |
|
| Issue Date FY: 2015 ( Subtotal = $1,151,844 ) |
| | 2015 | 2015 | PRECYTE INC | 970 PALO ALTO AVE | PALO ALTO | CA | 94301 | SANTA CLARA | USA | R44AG051282 | Optimization and Validation of an Indicator Cell Assay for Blood-Based Diagnosis of Alzheimer's Disease | 000 | 1 | NIH | 8/20/2015 | $1,151,844 |
|
|
